Healthy children and adolescents
Conditions
Interventions
Group 1: Typically developing participants (Age 10-18
n=34). anodal tDCS over lDLPFC (Study 1: before modeling)
Task: N-back
A: anodal tDCS + concurrent task
B: Sham stimulation + concurrent task
C: anodal tDCS before the task
D: sham stimulation be
n=17). anodal tDCS over rIFG (Study 1: before modeling)
Task: FlankerTask
A: anodal tDCS + concurrent task
B: Sham stimulation + concurrent task
C: anodal tDCS before the task
D: sham stimulation be
n=34). anodal tDCS over lDLPFC (Study 2: after modeling)
Task: N-back.
Stimulation with or without task depending on results from the study 1
A: Montage from study 1: anodal tDCS
B: sham stimula
n=17). anodal tDCS over rIFG (Study 2 after modeling)
Task: Flanker Task.
Stimulation with or without task depending on results from the study 1.
A: Montage from study 1: anodal tDCS
B: sham st
Sponsors
Universitätsklinikum Schleswig-Holstein Campus Kiel
Eligibility
Sex/Gender
All
Age
10 Years to 18 Years
Inclusion criteria
Inclusion criteria: • Age 10-18 years old, healthy females and males
Exclusion criteria
Exclusion criteria: • Past or present neurological diseases/brain surgery or psychiatric disorders • IQ < 80 • Birth weight < 2500 gr. • Born before the 37th week of pregancy • Concomitant medication • History of brain operations • Conduct disorder • Epilepsy/Epileptic seizure(s) in the past, family history of epileptic seizures • Migraine • Drug abuse • Only for MRI measurements: Any metallic implants in the skull area • Pregnancy (exclusion after pregnancy test at screening V1.0 T1) • History of craniocerebral injury with loss of consciousness • Any body electronic devices (hearing aid, heart pace maker e.c.) • Heart disease • Dermatological diseases on the skull • Participants with any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease or active neoplasia; • Tuberous sclerosis, neurofibromatosis, cerebral palsy, increased intracranial pressure • Any neurological or psychiatric medication for chronic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Overall accuracy in a n-back task (Working Memory (WM)) task immediately after stimula-tion/during stimulation • Overall accuracy in a Flanker task (assessing inhibitory/interference control) immediately after stimulation/during stimulation | — |
Secondary
| Measure | Time frame |
|---|---|
| • Reaction time and its variability as well as error rate in the n-back WM task. • Accuracy, reaction time, reaction time variability, omission and commission errors in the flanker task as well as continuous performance task. • Reaction time and reaction time variability in the flanker task. • Accuracy, reaction time, reaction time variability, omission and commission errors in the n-back WM task as well as continuous performance task • Safety and tolerability of tDCS assessed by (1) a standardized safety questionnaire as well as (2) EEG recordings before and after tDCS (EEG abnormalities such as slowing under the stimulating electrode or in remote brain areas, polarization asymmetries, spike-and-wave dis-changes). | — |
Countries
Germany, Portugal
Contacts
Public ContactVera Moliadze
Medizinische Psychologie und Medizinische Soziologie
Outcome results
None listed